Core Insights - McKesson Corporation (NYSE:MCK) has been recognized as one of the best performing stocks in the S&P 500 over the last five years [1] Financial Performance - BofA has reaffirmed a 'Buy' rating on McKesson and raised its price target from $950 to $970 following a strong third quarter performance [3] - The company reported third-quarter revenue of $106.16 billion, surpassing the forecast of $105.86 billion, and adjusted EPS of $9.34, exceeding the expected $9.22 [5] - McKesson raised its fiscal 2026 adjusted EPS forecast from a prior range of $38.35-$38.85 to a new range of $38.80-$39.20 [4] Segment Performance - The North American Pharmaceutical segment showed solid performance, contributing to the overall revenue growth [3] - The U.S. pharmaceutical segment's sales increased by 9% to $88.30 billion, driven by strong demand for specialty drugs and prescription volumes [5] Company Overview - McKesson Corporation is a healthcare services company that provides pharmaceutical distribution, specialty drug solutions, prescription technology services, and medical-surgical supplies in the U.S. and international markets [6]